glp 1 drugs and alzheimer's GLP-1 mimetics cognition Glucagon like peptide-1 (GLP-1) likes
Description
BMJ 381 , e073312 (2023)
Widenmaier SB, Kim SJ, Yang GK, et al
The main barriers are access and cost
Patients are accessing these medications through traditional physician offices, hospital-affiliated weight reduction centers, compounding pharmacies, and a rapidly expanding universe of online prescribing platforms
Because peace of mind matters
For many people, these medications are life-altering but they can also leave you with nutritional gaps
